Patents matching “intravenous”

US 12343350

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

US 12295929

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota · Granted May 13, 2025 · Expires May 8, 2045

US 2025002606

Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

BAVARIAN NORDIC AS [DK] · Granted Jan 2, 2025 · Expires Dec 28, 2044

US 12146150

Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

VOYAGER THERAPEUTICS, INC. · Granted Nov 19, 2024 · Expires Nov 14, 2044

US 2023302008

METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE

ALKERMES PHARMA IRELAND LTD [IE] · Granted Sep 28, 2023 · Expires Sep 23, 2043

US 11583540

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

US 11197869

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

SG 11202104918P

THERAPY FOR TREATING CANCER WITH AN INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF A RECOMBINANT MVA ENCODING 4-1BBL (CD137L) AND/OR CD40L

BAVARIAN NORDIC AS [DK] · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 10933042

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota · Granted Mar 2, 2021 · Expires Feb 25, 2041

US 10350183

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota · Granted Jul 16, 2019 · Expires Jul 11, 2039

US 10010534

Intravenous formulation and LC/MS/MS analysis method for GMC1

The Board of Regents of the University of Texas System · Granted Jul 3, 2018 · Expires Jun 28, 2038

US 9931311

Treating critically ill patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

US 9675572

Intravenous omega-3 fatty acid compositions and method of use

The United States of America as represented by the Secretary of the Army · Granted Jun 13, 2017 · Expires Jun 8, 2037

US 9649284

Treating critically ill patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted May 16, 2017 · Expires May 11, 2037

US 9295639

Treating critically ill patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Mar 29, 2016 · Expires Mar 24, 2036

US 9138404

Treating critically ill patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Sep 22, 2015 · Expires Sep 17, 2035

US 9114068

Treating patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Aug 25, 2015 · Expires Aug 20, 2035

US 9012508

Administration of intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Apr 21, 2015 · Expires Apr 16, 2035

US 8871810

Treating critically ill patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Oct 28, 2014 · Expires Oct 23, 2034

US 8735452

Treating patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted May 27, 2014 · Expires May 22, 2034